A French cohort study has found a significantly increased risk for leukemia in children born after fresh or frozen embryo transfer versus those conceived naturally.
Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
A thorough understanding of the relationship between viruses and hematologic cancers can help clinicians to deliver precise therapies and monitor potential complications.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
How do nutrition, supplements and antibiotics impact patient outcomes?
Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
A patient receiving arsenic trioxide for acute promyelocytic leukemia developed drug-induced acute pericarditis that was successfully treated with colchicine.
A case series of three patients suggests that obinutuzumab-induced acute thrombocytopenia is a frequent, possibly non-relapsing, and unique adverse event that deserves more attention than it currently receives.
Live: Monday 10 June 2024, from 16:30 – 18:00 (CEST)
In this live interactive webinar, a multidisciplinary team of speakers will provide practical guidance on managing patients with cutaneous T-cell lymphoma. Learn about the key aspects of diagnosis and treatment via a series of patient cases.
Approximately 60–70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients who relapse or are refractory to initial treatment have a poor prognosis. Chimeric antigen receptor …
Inotuzumab ozogamicin (BESPONSA™) is a CD22-targeted monoclonal antibody drug conjugate (ADC) developed by Pfizer for the treatment of CD22-postive B-cell precursor acute lymphoblastic leukaemia (ALL). Inotuzumab ozogamicin comprises a humanized …
Talicabtagene autoleucel (NexCAR19™) is a chimeric antigen receptor (CAR) T-cell therapy being developed by the Indian Institute of Technology, Bombay (IIT-B) and Immunoadoptive Cell Therapy (ImmunoACT) for the treatment of relapsed/refractory …
Currently available chimeric antigen receptor (CAR)-engineered T-cell therapies targeting B-cell maturation antigen (BCMA), namely, idecabtagene vicleucel and ciltacabtagene autoleucel, have shown marked efficacy against relapsed and refractory …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
A series of patient cases underpin this live interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.
Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.
Blinatumomab as a single agent has demonstrated superiority over salvage chemotherapy in patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), with manageable safety and efficacy. Though known to have anticipated drug …
A 67-year-old man underwent renal transplantation in his twenties. He developed refractory pleural effusion, with many large lymphocytes with severe atypia and mitosis in the effusion, indicating malignant lymphoma. He finally died of respiratory …
Flow-cytometry (FC) is a powerful tool that can assist in lymphoma diagnosis in lymph node (LN) specimens. Although lymphoma diagnosis and classification are mainly based on tumor cell characteristics, surrounding cells are less employed in this …
The most prevalent subtype of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL), and it originates from lymph nodes, extranodal organs, or tissues and can also transform from indolent lymphomas[ 1 , 2 ]. There has been a …
Mezigdomide has shown promising antitumor activity in combination with dexamethasone in a phase 1/2 trial comprising patients with relapsed and refractory multiple myeloma.
